Advertisement

Pharmacy World and Science

, Volume 20, Issue 3, pp 107–112 | Cite as

Pricing and Reimbursement of Pharmaceuticals. A New Culture for the Community Pharmacist.

  • Elisabeth Moen
  • Else‐Lydia Toverud
  • Jan Grund
  • Sissel Brinchmann
Article

Abstract

Pricing and reimbursement of pharmaceuticals are of concern for pharmacists. Different countries have different ways of organising their health care systems. The place for pharmaceuticals within these systems also differ. This article looks into the price‐ and reimbursement systems for medicinal products in Germany, Sweden, the UK and Norway. Various ways of organising the pharmaceutical market emerge. Some existing measures have been in place for a long time while others have been introduced more recently. A common goal for the four countries seems to be the drive to cut costs, and attempts to do this can be directed through various reimbursement systems, by focusing on prices or by influencing the physicians' prescribing behaviour, either through the use of advice or through the use of budgets. It is important for the pharmacists to have in‐depth knowledge of the price‐ and reimbursement system they have to work within in order to be of full service to their customers.

Pharmacoeconomics Pharmaceutical pricing Reimbursement systems Cost containment Reference pricing Co‐payment 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Poul Erik Pyndt. Paper on the systems of Price Control and Reimbursement of Medicine. MEFA (The Association of Danish Pharmaceutical Industry) 08.90.Google Scholar
  2. 2.
    Riksförsäkringsverket. Högkostnadsskydd vid köp av läkemedel. RFV Rekommenderar Allmänna råd 1996: 19, FKF 1528 96.12 TH.Google Scholar
  3. 3.
    Bundesministerium für Gesundheit. Die Gesetzliche Krankenversicherung. Bundesministerium für Gesundheit, Referat Öffentlichkeitsarbeit, April 1993.Google Scholar
  4. 4.
    Sosialdepartementet. Forskrifter om godtgjørelse av utgifter til viktigere legemidler. Sosialdepartementet, 19. desember 1984 (endret sist 12. oktober 1994).Google Scholar
  5. 5.
    Sosialdepartementet. Helsepolitikken mot år 2000: nasjonal helseplan. Sosialdepartementet 1988, Stortingsmelding nummer 41 (1987-88).Google Scholar
  6. 6.
    Norges offentlige utredninger (NOU). Piller, prioritering og politikk. NOU 1997: 7, Elanders Publishing AS, Oslo 1997.Google Scholar
  7. 7.
    McKee I, Laing W. Rationing medicine. A review of the implications of limiting the provision of health care resources. ABPI, Agenda for HEALTH, 1993.Google Scholar
  8. 8.
    Rigter H. Recent public policies in the Netherlands to control pharmaceutical pricing and reimbursement. Pharmaco Economics 1994;6(Suppl.1):15–21.Google Scholar
  9. 9.
    Norges offentlige utredninger (NOU). —Rammevilkår for omsetning av legemidler. NOU 1997: 6, Elanders Publishing AS, Oslo 1997.Google Scholar
  10. 10.
    Redwood H. Price regulation and pharmaceutical research-the limits of co-Existance. Felixstowe, UK: Oldwicks Press Limited, 1993.Google Scholar
  11. 11.
    Redwood H. The dynamics of drug pricing and reimbursement in the European Community. Felixstowe, UK: Oldwicks Press Limited, 1992.Google Scholar
  12. 12.
    Lasagna L, Werkö L. International differences in drug regulation philosophy. Int J Technol Assess Health Care 1986;2:615–18.Google Scholar
  13. 13.
    Grund J, Husbyn H. The role of pharmacoeconomics in health policy and management in Norway. Pharmaco Economics 1995;7(6):475–83.Google Scholar
  14. 14.
    ABPI. A guide to the Pharmaceutical Price Regulation Scheme (PPRS). ABPI 12 Whitehall London SW1A 2DY.Google Scholar
  15. 15.
    Sosial-og helsedepartementet. Forskrift om prisfastsettelse av legemidler. Sosialog helsedepartementet, 16. desember 1994.Google Scholar
  16. 16.
    Watts G. The UK's new price regulations-a triumph for industry? Scrip Magazine, November 1993.Google Scholar
  17. 17.
    Bloor K, Maynard A, Freemantle N. Lessons from international experience in controlling pharmaceutical expenditure III: regulating industry. BMJ 1996;313:33–5.Google Scholar
  18. 18.
    Department of Health. Working for patients. Cmnd 555, HMSO, London, 1989.Google Scholar
  19. 19.
    Coulter A, Bradlow J. Effect of NHS reforms on general practitioners' referral patterns. BMJ 1993;306:433–6.Google Scholar
  20. 20.
    Bloor K, Freemantle N. Lessons from international experience in controlling pharmaceutical expenditure II: influencing doctors. BMJ 1996;312:1525–7.Google Scholar
  21. 21.
    Schulenburg JM, Graf VD. The German health care system at the crossroads. Health Econ 1994;3:301–4.Google Scholar
  22. 22.
    Scrip. German reform effects. Scrip No 1861, 5 October 1993.Google Scholar

Copyright information

© Kluwer Academic Publishers 1998

Authors and Affiliations

  • Elisabeth Moen
    • 1
  • Else‐Lydia Toverud
    • 1
  • Jan Grund
    • 2
  • Sissel Brinchmann
    • 3
  1. 1.Department of Social Pharmacy, School of PharmacyUniversity of OsloOsloNorway
  2. 2.Norwegian School of ManagementSandvikaNorway
  3. 3.MSD (Norge) A/SDrammenNorway

Personalised recommendations